Literature DB >> 34185076

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

David N Louis1, Arie Perry2, Pieter Wesseling3,4, Daniel J Brat5, Ian A Cree6, Dominique Figarella-Branger7, Cynthia Hawkins8, H K Ng9, Stefan M Pfister10, Guido Reifenberger11, Riccardo Soffietti12, Andreas von Deimling13,14, David W Ellison15.   

Abstract

The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  World Health Organization; brain tumor; central nervous system; classification; diagnosis

Mesh:

Year:  2021        PMID: 34185076      PMCID: PMC8328013          DOI: 10.1093/neuonc/noab106

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  62 in total

1.  Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma.

Authors:  Ozgur Mete; Maria Beatriz Lopes; Sylvia L Asa
Journal:  Am J Surg Pathol       Date:  2013-11       Impact factor: 6.394

2.  Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations.

Authors:  Elke Pfaff; Christian Aichmüller; Martin Sill; Damian Stichel; Matija Snuderl; Matthias A Karajannis; Martin U Schuhmann; Jens Schittenhelm; Martin Hasselblatt; Christian Thomas; Andrey Korshunov; Marina Rhizova; Andrea Wittmann; Anna Kaufhold; Murat Iskar; Petra Ketteler; Dietmar Lohmann; Brent A Orr; David W Ellison; Katja von Hoff; Martin Mynarek; Stefan Rutkowski; Felix Sahm; Andreas von Deimling; Peter Lichter; Marcel Kool; Marc Zapatka; Stefan M Pfister; David T W Jones
Journal:  Acta Neuropathol       Date:  2019-11-25       Impact factor: 17.088

3.  Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO… and Shakespeare.

Authors:  David N Louis; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2017-08-11       Impact factor: 17.088

4.  Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.

Authors:  Elizabeth Vera-Bolanos; Kenneth Aldape; Ying Yuan; Jimin Wu; Khalida Wani; Mary Jo Necesito-Reyes; Howard Colman; Girish Dhall; Frank S Lieberman; Philippe Metellus; Tom Mikkelsen; Antonio Omuro; Sonia Partap; Michael Prados; H Ian Robins; Riccardo Soffietti; Jing Wu; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2014-08-13       Impact factor: 12.300

5.  Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.

Authors:  David W Ellison; Mehmet Kocak; Dominique Figarella-Branger; Giangaspero Felice; Godfraind Catherine; Torsten Pietsch; Didier Frappaz; Maura Massimino; Jacques Grill; James M Boyett; Richard G Grundy
Journal:  J Negat Results Biomed       Date:  2011-05-31

Review 6.  Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.

Authors:  Andreas von Deimling; Takahiro Ono; Mitsuaki Shirahata; David N Louis
Journal:  Semin Neurol       Date:  2018-03-16       Impact factor: 3.420

7.  ISNO consensus guidelines for practical adaptation of the WHO 2016 classification of adult diffuse gliomas.

Authors:  Vani Santosh; Palavalasa Sravya; Tejpal Gupta; Dattatraya Muzumdar; Geeta Chacko; Vaishali Suri; Sridhar Epari; Anandh Balasubramaniam; Bishan Dass Radotra; Sandip Chatterjee; Chitra Sarkar; Rakesh Jalali
Journal:  Neurol India       Date:  2019 Jan-Feb       Impact factor: 2.117

8.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

9.  Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool.

Authors:  L P Priesterbach-Ackley; H B Boldt; J K Petersen; N Bervoets; D Scheie; B P Ulhøi; M Gardberg; T Brännström; S H Torp; E Aronica; B Küsters; W F A den Dunnen; F Y F L de Vos; P Wesseling; W W J de Leng; B W Kristensen
Journal:  Neuropathol Appl Neurobiol       Date:  2020-02-18       Impact factor: 8.090

10.  Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.

Authors:  Tanvi Sharma; Edward C Schwalbe; Daniel Williamson; Martin Sill; Volker Hovestadt; Martin Mynarek; Stefan Rutkowski; Giles W Robinson; Amar Gajjar; Florence Cavalli; Vijay Ramaswamy; Michael D Taylor; Janet C Lindsey; Rebecca M Hill; Natalie Jäger; Andrey Korshunov; Debbie Hicks; Simon Bailey; Marcel Kool; Lukas Chavez; Paul A Northcott; Stefan M Pfister; Steven C Clifford
Journal:  Acta Neuropathol       Date:  2019-05-10       Impact factor: 17.088

View more
  811 in total

1.  A case of primary CNS embryonal rhabdomyosarcoma with PAX3-NCOA2 fusion and systematic meta-review.

Authors:  Ryuma Tanaka; Kyohei Inoue; Yuji Yamada; Masanori Yoshida; Haruko Shima; Jumpei Ito; Hajime Okita; Tomoru Miwa; Motohiro Kato; Hiroyuki Shimada
Journal:  J Neurooncol       Date:  2021-08-16       Impact factor: 4.130

Review 2.  Major Features of the 2021 WHO Classification of CNS Tumors.

Authors:  Heather L Smith; Nitin Wadhwani; Craig Horbinski
Journal:  Neurotherapeutics       Date:  2022-05-16       Impact factor: 7.620

Review 3.  The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.

Authors:  Huy Gia Vuong; Tam N M Ngo; Hieu Trong Le; Ian F Dunn
Journal:  J Neurooncol       Date:  2022-05-23       Impact factor: 4.130

4.  Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.

Authors:  Arian Lasocki; Michael E Buckland; Katharine J Drummond; Heng Wei; Jing Xie; Michael Christie; Andrew Neal; Frank Gaillard
Journal:  Neuroradiology       Date:  2022-05-24       Impact factor: 2.804

Review 5.  Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians.

Authors:  Justin T Low; Quinn T Ostrom; Gino Cioffi; Corey Neff; Kristin A Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neurooncol Pract       Date:  2022-02-22

6.  Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype.

Authors:  Leihao Ren; Lingyang Hua; Zhongyuan Bao; Hiroaki Wakimoto; Ye Gong; Jiaojiao Deng; Daijun Wang; Jiawei Chen; Hong Chen; Tareq A Juratli
Journal:  J Neurooncol       Date:  2022-05-25       Impact factor: 4.130

7.  Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.

Authors:  Vasileios K Kavouridis; Keith L Ligon; Patrick Y Wen; J Bryan Iorgulescu
Journal:  J Neurooncol       Date:  2022-04-26       Impact factor: 4.130

8.  Radio-Pathomic Maps of Cell Density Identify Brain Tumor Invasion beyond Traditional MRI-Defined Margins.

Authors:  S A Bobholz; A K Lowman; M Brehler; F Kyereme; S R Duenweg; J Sherman; S D McGarry; E J Cochran; J Connelly; W M Mueller; M Agarwal; A Banerjee; P S LaViolette
Journal:  AJNR Am J Neuroradiol       Date:  2022-04-14       Impact factor: 3.825

9.  The role of apparent diffusion coefficient histogram metrics for differentiating pediatric medulloblastoma histological variants and molecular groups.

Authors:  Fabrício Guimarães Gonçalves; Luis Octavio Tierradentro-Garcia; Jorge Du Ub Kim; Alireza Zandifar; Adarsh Ghosh; Angela N Viaene; Dmitry Khrichenko; Savvas Andronikou; Arastoo Vossough
Journal:  Pediatr Radiol       Date:  2022-07-08

Review 10.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.